Distinguished Financial Researcher, Educator and Bitcoin Specialist Nik Bhatia Releases Definitive New Book Detailing Bitcoin History and Emerging Future in Changing Financial Landscape

TipRanks

3 Monster Growth Stock Ready to Run Higher

What you can do from the standard market disclaimer, ‘past performance cannot guarantee future earnings.’ Should you avoid all stocks that have shown tremendous growth in recent months? Or should you just ignore it, and focus on the equity that values ​​quickly? The keen investor takes a smart middle path, treating stocks as individuals and evaluating them on a case-by-case basis. Past performance is not a guarantee, but it can be an indicator, especially a consistent long-term performance. But that is only one part of the growth stock picture. Investors should also look for Wall Street’s view – are analysts impressed by the stock? And in addition, what does the potential look like upside down? Now we have a handy profile for monster growth stocks: gangbusters earnings, Buying ratings from Wall Street’s analyst corps, and an upside down for the coming year. Three stocks in the TipRanks database highlight all those signs of strong forward growth. Here are the details. OptimizeRx Corporation (OPRX) The ongoing health crisis has had a major impact on our digital world, accelerating the move to online records and information. OptimizeRx operates a digital platform that facilitates communication between the various branches of the healthcare environment – doctors, pharmacies, patients – at the point of care. The value of this service is evident from the stock’s huge gains in recent months: over the past 52 weeks, OPRX shares are up 277%. It’s not just share earnings that are high. Since 3Q19, the company has reported front-line revenue gains in each quarter. The most recent, 3Q20, saw revenue of $ 10.52 million, a record for the company. Year-over-year earnings were 110%; for the first 9 months of 2020, the company’s revenue was $ 26.9 million – another record, and up 56% from the same period in 2019. In other metrics, OptimizeRx indicated it had $ 12 million in cash on hand at the end of Q3 , and reported that it closed two additional venture deals in the quarter, bringing the total value of annual recurring revenue to $ 21 million. OprimizeRx’s rapid growth has impressed Roth Capital analyst Rick Baldry, and he’s not shy about saying so. “Given that its RFP pipeline doubled year-on-year in 3Q20, we believe OPRX could accelerate organic growth to 100% in 2020… [We] note that OPRX’s RFP pipeline growth may not fully reflect its growth potential in 2021 given that its recent machine learning platform extension announcement (and its associated data partnership with Komodo Health that tracks 320M patients annually) is skewed from forecasts in pursuit of R&D and patents, “Baldry chose. Overall, the 5-star analyst summed up,” Given that we expect both materials upside down with current forecasts, OPRX is our Best Option at 2021. “In line with these bullish comments, Baldry is rating OPRX and Buy, and his $ 70 price target suggests an upside potential of 77% for the next 12 months. (To watch Baldry’s story, click here) Wall Street clearly agrees with Baldry, as evidenced by the Strong Buy unanimous consensus rating, based on 3 recent analyst reviews.The shares are selling for $ 39.54, and have an average price target of $ 53.33 suggests room for ~ 35% growth this year. (See OPRX stock analysis on TipRanks) Lovesac (LOVE) Next up is a furniture company, known for its modular seating systems and bean bag seats. Lovesac offers customers an easily adjustable seating arrangement that can fit any room, home or style – and easily adapt to the changing mood of owners. The company has been named one of the fast-growing furniture makers of the past decade, and reported a total of $ 165.9 million for fiscal 2019. Lovesac’s rising revenue was clear at 3Q20, when the company reported net sales growth of 43.5% year-on-year, to $ 74.7 million. Net income changed from a loss of $ 6.7 million in the year-ago quarter to a profit of $ 2.5 million in Q3 this year. Gross profit improved 10% yoy to 55.3%. That strong sales and financial performance drove share appreciation 283% over the last 52 weeks. Covering LOVE for BTIG, analyst Camilo Lyon says, “LOVE leverages the current COVID-19 crisis and the work of the home environment as consumers shift their purchases to home-related goods. The company has successfully mobilized its resources to support online sales, even relocating its full-time associates to interact with customers online through instant messaging and product demos on social media. ”Lyon believes the company’s moves position it successfully to thrive in a post-COVID world, modeling” 27% annual revenue growth for the next two years as brand awareness grows, new customers coming brand, and new product introductions give existing customers more. reasons to shop the brand. ”To this end, Lyon gives LOVE a Buy rating, while its $ 62 price target suggests room for upside growth down 26% in 2021. (To view Lyon history, click here) Overall, there are 4 recent reviews on LOVE and all are Buy, achieving a consensus rating of a unanimous Strong Buy analyst. LOVE’s share appreciation has pushed the price of stock close to the average target of $ 56.75, leaving up 16% upside from the current $ 48.88 trading price. (See LOVE stock analysis on TipRanks) Kirkland (KIRK) The ongoing corona crisis has done more than just pushing white-collar workers into remote office and telecommunications situations ll. By forcing large numbers of people to stay home, the pandemic – and the government’s response – has made potential home furniture customers look long in their living areas. Lovesac, above, is not the only company that has benefited; Kirkland’s, a home décor and miscellaneous furniture retailer with over 380 stores in 35 provinces plus an active online presence, is anothe r. Kirkland’s, like the other stocks on this list, has shown strong earnings growth and share appreciation in the past year. The company’s latest quarterly results, for 3Q20, revealed front-line revenue of $ 146.6 million, slightly over the analyst forecast and up just year-over-year. Earnings showed stronger gains. Q3’s EPS was 66 cents per share, far better than the 53-cent loss recorded in 3Q19. Share appreciation has matched these gains, to say the least. KIRK has increased by 1500% in the last 12 months, a huge increase that reflects the company’s success in adapting to the growing importance of online sales. This strong growth has attracted the attention of Craig-Hallum analyst Jeremy Hamblin. “[Kirkland’s] continues to ignite on all cylinders … While the company is likely to benefit from some industry tails, it is clear that strategic initiatives to improve margins have sustainability while investments in an Ecommerce platform should improve (up 50% in Q3) help offset shop closures … we … note that KIRK has a stronger overall balance sheet with better FCF (mid-teens) output than its peer group, ”wrote Hamblin. Accordingly, Hamblin rates KIRK and Buy stock and sets a $ 32 price target, suggesting an upside of 65% of the $ 19.38 share price. (To watch Hamblin’s history, click here) Some stocks fly under the radar, and KIRK is one of those. Hamblin’s is the only recent analyst review of this company, and it is decidedly positive. (See KIRK stock analysis on TipRanks) To find good ideas for growth stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the analysts concerned. The content is intended for informational use only. It is very important to do your own analysis before making any investment.

Source